Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Phase 1/2 clinical trial is to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IDP-121 combined with chemotherapy in patients with advanced unresectable/metastatic SCLC that have progressed after 1st line platinum- based chemotherapy, considering the role of MYC amplification in the development of platinum resistance.
Epistemonikos ID: d8b023241c9731971d6beb22ad96e0badd5c195d
First added on: Oct 08, 2026